Ihre E-Mail wurde erfolgreich gesendet. Bitte prüfen Sie Ihren Maileingang.

Leider ist ein Fehler beim E-Mail-Versand aufgetreten. Bitte versuchen Sie es erneut.

Vorgang fortführen?

Exportieren
  • 1
    In: Journal of Gastroenterology and Hepatology, Wiley, Vol. 30, No. 3 ( 2015-03), p. 540-545
    Kurzfassung: We aimed to explore the effectiveness of preventive usage of hepatoprotectors in patients with tuberculosis ( TB ) receiving anti‐ TB treatment. Methods With stratified cluster sampling strategy, a prospective cohort with 4488 sputum smears positive pulmonary TB patients was established from 52 counties of four regions in C hina. During anti‐ TB treatment, prescriptions of hepatoprotectors were documented in detail, and liver enzymes were routinely monitored. A nti‐ TB drug‐induced liver injury ( ATLI ) was assessed based on liver enzymes following the criteria of A merican T horacic Society. The incidence of ATLI between the preventive usage group and reference group was compared by propensity score adjusted C ox proportional hazard analysis. Preexisting diseases, history of liver disease, hepatitis B surface antigen status, primary/re‐treatment of TB , income per year, and liver enzymes before anti‐ TB treatment were included in the propensity score model. Results After 6–9 months of follow‐up and monitoring, 4304 patients sustained in our cohort. Two thousand seven hundred fifty‐two (63.9%) patients preventively took hepatoprotectors with a median course of 183 days. Most frequently used drugs were H u G an P ian, silymarin, glucurone, and inosine. Two thousand one hundred forty‐four (77.9%) patients took those drugs more than 6 months. Sixty‐nine (2.4%) patients of preventive usage group and 37 (2.5%) of reference group experienced ATLI , respectively. Statistical significances were not found by propensity score analysis for the association between using hepatoprotectors (hazard ratio[HR]  = 0.99, 95% confidence interval [ CI ]: 0.65–1.52), using hepatoprotectors in the whole course ( HR  = 0.94, 95% CI : 0.60–1.48), using H u G an P ians, silymarin, glucurone, and inosine with ATLI occurrence. Conclusions N o preventive effect of hepatoprotectors was observed in patients receiving anti‐ TB treatment.
    Materialart: Online-Ressource
    ISSN: 0815-9319 , 1440-1746
    URL: Issue
    Sprache: Englisch
    Verlag: Wiley
    Publikationsdatum: 2015
    ZDB Id: 2006782-3
    Bibliothek Standort Signatur Band/Heft/Jahr Verfügbarkeit
    BibTip Andere fanden auch interessant ...
Schließen ⊗
Diese Webseite nutzt Cookies und das Analyse-Tool Matomo. Weitere Informationen finden Sie auf den KOBV Seiten zum Datenschutz